Phase 2 Osteoarthritis Trial, Recruiting NCT05986292 Sponsor: Eli Lilly and Company Condition: Osteoarthritis
Back to Osteoarthritis

Phase 2 Osteoarthritis Trial, Recruiting

NCT05986292
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People whose pain level falls between 40 and 95 on a standard pain rating scale (called a Visual Analog Scale) at the time of initial screening.
  • People who have experienced daily pain for at least 12 weeks, based on their own report or their medical records.
  • People who score 30 or below on a questionnaire that measures pain-related negative thinking (called the Pain Catastrophizing Scale).
  • People with a body mass index (a measure of body weight relative to height) below 40.
  • People who are willing to keep their current non-medication pain treatments (such as physical therapy) unchanged and not start any new ones during the study.
  • People who are willing to stop all medications taken for chronic pain during the study, except for one allowed rescue medication.

Who may not be able to join:

  • People with certain serious heart rhythm problems, including second- or third-degree heart block, AV dissociation, or a history of a dangerous rapid heartbeat (ventricular tachycardia).
  • People who have had a procedure in the past 6 months designed to permanently reduce feeling in the area where their pain is located (such as nerve ablation).
  • People who have any surgery planned during the study period, for any reason.
  • People who have an acute, serious, or unstable health condition, or any other medical illness that the study doctor believes would make participation unsafe.
  • People who have had cancer within the past 2 years, with the exception of certain common skin cancers (basal cell or squamous cell carcinoma) that were fully removed by surgery.
  • People who have fibromyalgia.
  • People who have a substance use disorder as defined by the current standard medical guidelines (DSM-5).
  • People who have any significant abnormal findings at screening in their physical exam, neurological exam, vital signs, heart tracing (ECG), or blood/lab tests that the study doctor considers concerning.
  • People who test positive for HIV at screening.
  • People who have a history of alcohol, illegal drug, painkiller, or narcotic use disorder within the 2 years before screening.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Phone: 1-317-615-4559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
30 January 2020
Est. completion
1 April 2027

Where this trial is recruiting

Puerto Rico 🇺🇸 United States

Primary endpoints

Number of Participants Who Were Allocated to Each ISA

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov